Actively Recruiting
68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy
Led by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Updated on 2025-02-20
20
Participants Needed
1
Research Sites
180 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Upper gastrointestinal (GI) cancers are a major health problem in Canada. At the metastatic stage, options are limited (usually chemotherapy, immunotherapy, personalized therapies under research protocols). These options are not applicable to all patients and may have significant toxicities. Endoradiotherapy (ERT) using a radioisotope coupled with a localization vector specifically targeting tumor cells to deliver a localized dose of radiation therapy is a promising avenue as it can treat disseminated neoplastic disease in a specific manner sparing healthy tissue with minimal side effects. The main goal of this study is to confirm that patients with upper GI cancer would be eligible for ERT (177Lu-PSMA treatment by using 68Ga-PSMA PET/CT assessment).
CONDITIONS
Official Title
68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years and older
- Diagnosed with active adenocarcinoma of the esophagus, stomach, bile ducts, or pancreas confirmed by a CT scan within the last 8 weeks
- At least one lesion identified as stable or progressive cancer on CT imaging
- No local therapy (such as radiotherapy or ablation) applied to lesions between the CT scan and 68Ga-PSMA PET imaging
- Able to give free and informed consent
- Able to undergo 68Ga-PSMA PET imaging within 2 months of the qualifying CT scan
You will not qualify if you...
- Having another active cancer, except non-metastatic non-melanoma skin cancer or cancers in remission for at least 3 years
- ECOG performance status greater than 3
- Being pregnant
- Unable to follow study rules
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CIUSSS de l'Estrie- CHUS Hospital
Sherbrooke, Quebec, Canada, J1H 5N4
Actively Recruiting
Research Team
A
Amélie Tétu, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here